文献速递神经肿瘤

G-四链体稳定剂CX-5461与放疗有效联合靶向α-地中海贫血/智力障碍X连锁缺陷型恶性胶质瘤

G-quadruplex stabilizer CX-5461 effectively combines with radiotherapy to target α-thalassemia/mental retardation X-linked-deficient malignant glioma.
PubMed 文献 · Neuro Oncol · 2025-01-01

在ATRX缺陷的临床前胶质瘤模型中,G4稳定剂CX-5461单药或联合电离辐射可选择性增强DNA损伤和细胞死亡;CX-5461/IR联合治疗显著延迟肿瘤生长并延长小鼠生存,机制涉及破坏H3.3沉积、增强复制应激、激活不依赖p53的凋亡及诱导G2/M阻滞。

要点

  • CX-5461在ATRX缺陷胶质瘤干细胞中诱导剂量敏感性致死,并增强复制应激和DNA损伤。
  • CX-5461联合放疗在ATRX缺陷侧腹异种移植中显著延迟肿瘤生长并延长生存。
  • 全身CX-5461虽血脑屏障穿透欠佳,但在颅内模型中仍产生可检测的药效学效应。

核心结论

  • 本研究实质性证明G4稳定化靶向ATRX缺陷恶性胶质瘤的有效性并阐明作用机制,为临床转化奠定基础。

研究设计与样本

  • 使用G4稳定剂CX-5461处理患者来源胶质瘤干细胞(GSC)体外实验,以及GSC侧腹和颅内小鼠异种移植体内实验,评估单药及联合电离辐射(IR)的疗效。

主要发现

  • CX-5461在ATRX缺陷GSC中相比ATRX完整对照促进剂量敏感性致死。
  • 机制研究显示CX-5461在ATRX缺陷GSC中比ATRX完整对照更大程度地破坏组蛋白变体H3.3沉积、增强复制应激和DNA损伤、激活不依赖p53的凋亡并诱导G2/M阻滞。
  • 体内数据证实CX-5461/IR治疗在ATRX缺陷侧腹异种移植小鼠中深度延迟肿瘤生长并延长生存。
  • 组织病理学分析显示CX-5461单药及联合IR治疗的肿瘤中增殖降低、凋亡增加,并显著诱导G4、复制应激和DNA损伤。
  • 尽管血脑屏障穿透欠佳,全身CX-5461治疗在ATRX缺陷颅内GSC模型中诱导可检测的药效学效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inactivation of α-thalassemia/mental retardation X-linked (ATRX) represents a defining molecular feature in large subsets of malignant glioma. ATRX deficiency gives rise to abnormal G-quadruplex (G4) DNA secondary structures, enhancing replication stress and genomic instability. Building on earlier work, we evaluated the extent to which pharmacological G4 stabilization selectively enhances DNA damage and cell death in ATRX-deficient preclinical glioma models. METHODS: Using the G4 stabilizer CX-5461, we treated patient-derived glioma stem cells (GSCs) in vitro and GSC flank and intracranial murine xenografts in vivo to evaluate efficacy as both a single agent and in combination with ionizing radiation (IR), the latter a central element of current treatment standards. RESULTS: CX-5461 promoted dose-sensitive lethality in ATRX-deficient GSCs relative to ATRX-intact controls. Mechanistic studies revealed that CX-5461 disrupted histone variant H3.3 deposition, enhanced replication stress and DNA damage, activated p53-independent apoptosis, and induced G2/M arrest to a greater extent in ATRX-deficient GSCs than in ATRX-intact counterparts. These data were corroborated in vivo, where CX-5461/IR treatment profoundly delayed tumor growth and prolonged survival in mice bearing ATRX-deficient flank xenografts. Histopathological analyses revealed decreased proliferation, increased apoptosis, and significant G4 induction, replication stress, and DNA damage in CX-5461-treated tumors, both alone and in combination with IR. Finally, despite suboptimal blood-brain-barrier penetration, systemic CX-5461 treatment induced tangible pharmacodynamic effects in ATRX-deficient intracranial GSC models. CONCLUSIONS: In totality, our work substantively demonstrates efficacy and defines mechanisms of action for G4 stabilization as a novel therapeutic strategy targeting ATRX-deficient malignant glioma, laying the groundwork for clinical translation.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Dharmaiah S, Malgulwar PB, Johnson WE, et al. G-quadruplex stabilizer CX-5461 effectively combines with radiotherapy to target α-thalassemia/mental retardation X-linked-deficient malignant glioma. Neuro Oncol. 2025. PMID: 39570009. doi:10.1093/neuonc/noae248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。